-
EP1928903
European procedure
Extract from the Register of European Patents
EP About this file: EP1928903
| EP1928903 - CELL-PERMEABLE PEPTIDE INHIBITORS OF THE JNK SIGNAL TRANSDUCTION PATHWAY [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 05.04.2013 Database last updated on 01.04.2026 | Most recent event Tooltip | 05.04.2013 | No opposition filed within time limit | published on 08.05.2013 [2013/19] | Applicant(s) | For all designated states Xigen S.A. Route de la Corniche 4 1066 Epalinges / CH | [2012/17] |
| Former [2008/24] | For all designated states Xigen S.A. Rue des Terreaux 17 (4ème étage) 1003 Lausanne / CH | Inventor(s) | 01 /
BONNY, Christophe 37c, chemin du Trabandan CH-1006 Lausanne / CH | [2008/24] | Representative(s) | Graf von Stosch, Andreas, et al Graf von Stosch Patentanwaltsgesellschaft mbH Triftstraße 5 80538 München / DE | [N/P] |
| Former [2009/29] | Graf von Stosch, Andreas, et al Graf von Stosch Patentanwaltsgesellschaft mbH Prinzregentenstrasse 22 80538 München / DE | ||
| Former [2008/52] | Graf von Stosch, Andreas, et al Graf von Stosch Patentanwaltsgesellschaft mbH Prinzregentenstrasse 22 80538 München / DE | ||
| Former [2008/40] | Graf von Stosch, Andreas, et al Bosch Graf von Stosch Jehle Patentanwaltsgesellschaft mbH Prinzregentenstrasse 22 80538 München / DE | ||
| Former [2008/24] | Graf von Stosch, Andreas, et al Bosch Graf von Stosch Jehle Patentanwaltsgesellschaft mbH Flüggenstrasse 13 80639 München / DE | Application number, filing date | 06792004.1 | 12.09.2006 | [2008/24] | WO2006EP08882 | Priority number, date | WO2005EP09782 | 12.09.2005 Original published format: PCT/EP2005/009782 | [2008/24] | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | WO2007031280 | Date: | 22.03.2007 | Language: | EN | [2007/12] | Type: | A2 Application without search report | No.: | EP1928903 | Date: | 11.06.2008 | Language: | EN | The application published by WIPO in one of the EPO official languages on 22.03.2007 takes the place of the publication of the European patent application. | [2008/24] | Type: | B1 Patent specification | No.: | EP1928903 | Date: | 30.05.2012 | Language: | EN | [2012/22] | Search report(s) | International search report - published on: | EP | 24.05.2007 | Classification | IPC: | C07K14/47 | [2008/24] | CPC: |
A61P3/10 (EP);
C07K14/47 (KR,NO,US);
C07K14/005 (US);
A61K38/17 (NO);
A61P11/00 (EP);
A61P11/16 (EP);
A61P17/00 (EP);
A61P17/02 (EP);
A61P17/06 (EP);
A61P19/02 (EP);
A61P27/16 (EP);
A61P29/00 (EP);
A61P31/04 (EP);
A61P31/18 (EP);
A61P35/00 (EP);
A61P35/02 (EP);
A61P37/00 (EP);
A61P37/02 (EP);
A61P37/04 (EP);
A61P37/06 (EP);
A61P37/08 (EP);
A61P39/06 (EP);
A61P43/00 (EP);
A61P7/08 (EP);
A61P9/00 (EP);
A61P9/10 (EP);
A61P9/12 (EP);
A61P9/14 (EP);
C07K14/4703 (EP,NO,US);
C07K16/18 (US);
C07K19/00 (NO);
C07K7/08 (US);
C12N15/62 (NO);
C12N7/00 (US);
A61K38/00 (EP,US);
C07K2319/10 (US);
| Designated contracting states | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR [2008/24] | Extension states | AL | 28.02.2008 | BA | 28.02.2008 | HR | 28.02.2008 | MK | 28.02.2008 | RS | 28.02.2008 | Title | German: | ZELLDURCHLÄSSIGE PEPTIDHEMMER DES JNK-SIGNALTRANSDUKTIONSWEGES | [2008/24] | English: | CELL-PERMEABLE PEPTIDE INHIBITORS OF THE JNK SIGNAL TRANSDUCTION PATHWAY | [2008/24] | French: | INHIBITEURS PEPTIDIQUES PERMEABLES AUX CELLULES DE LA VOIE DE TRANSDUCTION DE SIGNAL JNK | [2008/24] | Entry into regional phase | 10.01.2008 | National basic fee paid | 10.01.2008 | Designation fee(s) paid | 10.01.2008 | Examination fee paid | Examination procedure | 10.01.2008 | Examination requested [2008/24] | 12.06.2009 | Despatch of a communication from the examining division (Time limit: M06) | 28.01.2010 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time | 30.03.2010 | Reply to a communication from the examining division | 08.11.2011 | Date of oral proceedings | 18.01.2012 | Minutes of oral proceedings despatched | 27.01.2012 | Communication of intention to grant the patent | 29.03.2012 | Fee for grant paid | 29.03.2012 | Fee for publishing/printing paid | Divisional application(s) | EP11003985.6 / EP2418217 | EP15002528.6 / EP3012266 | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 12.06.2009 | Opposition(s) | 01.03.2013 | No opposition filed within time limit [2013/19] | Request for further processing for: | The application is deemed to be withdrawn due to failure to reply to the examination report | 30.03.2010 | Request for further processing filed | 30.03.2010 | Full payment received (date of receipt of payment) Request granted | 23.04.2010 | Decision despatched | Fees paid | Renewal fee | 26.05.2008 | Renewal fee patent year 03 | 13.07.2009 | Renewal fee patent year 04 | 13.09.2010 | Renewal fee patent year 05 | 12.09.2011 | Renewal fee patent year 06 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [XY] BORSELLO TIZIANA ET AL: "A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia.", NATURE MEDICINE. SEP 2003, vol. 9, no. 9, September 2003 (2003-09-01), pages 1180 - 1186, XP002366119, ISSN: 1078-8956 [X] 1-13 * the whole document * [Y] 14-23 DOI: http://dx.doi.org/10.1038/nm911 | [XY] BONNY C ET AL: "Cell-permeable peptide inhibitors of JNK: novel blockers of beta-cell death", DIABETES, NEW YORK, NY, US, vol. 50, no. 1, January 2001 (2001-01-01), pages 77 - 82, XP002274267, ISSN: 0012-1797 [X] 1-13 * the whole document * [Y] 14-23 DOI: http://dx.doi.org/10.2337/diabetes.50.1.77 | [XY] BARR R K ET AL: "IDENTIFICATION OF THE CRITICAL FEATURES OF A SMALL PEPTIDE INHIBITOR OF JNK ACTIVITY", JOURNAL OF BIOLOGICAL CHEMISTRY, THE AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, INC.,, US, vol. 277, no. 13, 29 March 2002 (2002-03-29), pages 10987 - 10997, XP001155759, ISSN: 0021-9258 [X] 1-6 * table 1 *[Y] 7-23 DOI: http://dx.doi.org/10.1074/jbc.M107565200 | [Y] VIVES E ET AL: "A TRUNCATED HIV-1 TAT PROTEIN BASIC DOMAIN RAPIDLY TRANSLOCATES THROUGH THE PLASMA MEMBRANE AND ACCUMULATES IN THE CELL NUCLEUS", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 272, no. 25, 1997, pages 16010 - 16017, XP002931299, ISSN: 0021-9258 [Y] 7-23 * figure 1 * DOI: http://dx.doi.org/10.1074/jbc.272.25.16010 | [Y] BORSELLO TIZIANA ET AL: "Use of cell-permeable peptides to prevent neuronal degeneration.", TRENDS IN MOLECULAR MEDICINE. MAY 2004, vol. 10, no. 5, May 2004 (2004-05-01), pages 239 - 244, XP002366120, ISSN: 1471-4914 [Y] 1-23 * the whole document * DOI: http://dx.doi.org/10.1016/j.molmed.2004.03.008 | [Y] BONNY CHRISTOPHE ET AL: "Targeting the JNK pathway as a therapeutic protective strategy for nervous system diseases.", REVIEWS IN THE NEUROSCIENCES. 2005, vol. 16, no. 1, 2005, pages 57 - 67, XP009061133, ISSN: 0334-1763 [Y] 1-23 * the whole document * | [Y] DATABASE UniProt 28 February 2003 (2003-02-28), XP002366175, retrieved from EBI Database accession no. Q9WVI9 [Y] 1-23 * column A * | Examination | TACHIBANA H ET AL: "JNK1 is required to preserve cardiac function in the early response to pressure overload", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 343, no. 4, 19 May 2006 (2006-05-19), pages 1060 - 1066, XP024924816, ISSN: 0006-291X, [retrieved on 20060519], DOI: DOI:10.1016/J.BBRC.2006.03.065 DOI: http://dx.doi.org/10.1016/j.bbrc.2006.03.065 | KUAN CHIA-YI ET AL: "A critical role of neural-specific JNK3 for ischemic apoptosis.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 9 DEC 2003 LNKD- PUBMED:14657393, vol. 100, no. 25, 9 December 2003 (2003-12-09), pages 15184 - 15189, ISSN: 0027-8424 | CHANG LUFEN ET AL: "JNK1 is required for maintenance of neuronal microtubules and controls phosphorylation of microtubule-associated proteins.", DEVELOPMENTAL CELL APR 2003 LNKD- PUBMED:12689591, vol. 4, no. 4, April 2003 (2003-04-01), pages 521 - 533, ISSN: 1534-5807 | CHOI HONG SEOK ET AL: "c-Jun N-terminal kinase 1 phosphorylates Myt1 to prevent UVA-induced skin cancer.", MOLECULAR AND CELLULAR BIOLOGY APR 2009 LNKD- PUBMED:19204086, vol. 29, no. 8, April 2009 (2009-04-01), pages 2168 - 2180, ISSN: 1098-5549 | WESTWICK J.K. ET AL: "Activation of Jun kinase is an early event in hepatic regeneration.", THE JOURNAL OF CLINICAL INVESTIGATION FEB 1995 LNKD- PUBMED:7860764, vol. 95, no. 2, February 1995 (1995-02-01), pages 803 - 810, ISSN: 0021-9738 | HUNOT STPHANE ET AL: "JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 13 JAN 2004 LNKD- PUBMED:14704277, vol. 101, no. 2, 13 January 2004 (2004-01-13), pages 665 - 670, ISSN: 0027-8424 | SUMARA G ET AL: "Jnking atherosclerosis", CMLS CELLULAR AND MOLECULAR LIFE SCIENCES, BIRKHUSER-VERLAG, BA, vol. 62, no. 21, 1 November 2005 (2005-11-01), pages 2487 - 2494, XP019200875, ISSN: 1420-9071, DOI: DOI:10.1007/S00018-005-5253-6 DOI: http://dx.doi.org/10.1007/s00018-005-5253-6 | JAESCHKE ANJA ET AL: "Disruption of the Jnk2 (Mapk9) gene reduces destructive insulitis and diabetes in a mouse model of type I diabetes.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 10 MAY 2005 LNKD- PUBMED:15867147, vol. 102, no. 19, 10 May 2005 (2005-05-10), pages 6931 - 6935, ISSN: 0027-8424 | BOST FREDERIC ET AL: "The Jun kinase 2 isoform is preferentially required for epidermal growth factor-induced transformation of human A549 lung carcinoma cells", MOLECULAR AND CELLULAR BIOLOGY, AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON, US, vol. 19, no. 3, 1 March 1999 (1999-03-01), pages 1938 - 1949, XP002169471, ISSN: 0270-7306 | AHMED SHAFIQ UDDIN ET AL: "Basal cancer cell survival involves JNK2 suppression of a novel JNK1/c-Jun/Bcl-3 apoptotic network.", PLOS ONE 2009 LNKD- PUBMED:19806201, vol. 4, no. 10, 2009, pages e7305, ISSN: 1932-6203 |